Ninety-Day Readmission and Long-Term Mortality in Medicare Patients (≥65 Years) Treated With Ticagrelor Versus Prasugrel After Percutaneous Coronary Intervention (from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium)-Reference-Cited by-同舟云学术

Ninety-Day Readmission and Long-Term Mortality in Medicare Patients (≥65 Years) Treated With Ticagrelor Versus Prasugrel After Percutaneous Coronary Intervention (from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium)

Published:2017-12 Issue:11 Volume:120 Page:1926-1932
ISSN:0002-9149
Container-title:The American Journal of Cardiology
language:en
Short-container-title:The American Journal of Cardiology

Author:

Song Chris,Sukul Devraj^ORCID,Seth Milan,Dupree James M.^ORCID,Khandelwal Akshay,Dixon Simon R.,Wohns David,LaLonde Thomas,Gurm Hitinder S.

Funder

National Institutes of Health T32 postdoctoral research training grant

Blue Cross Blue Shield of Michigan and Blue Care Network

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference26 articles.

1. Ticagrelor versus clopidogrel in patients with acute coronary syndromes;Wallentin;N Engl J Med,2009

2. Prasugrel versus clopidogrel in patients with acute coronary syndromes;Wiviott;N Engl J Med,2007

3. Prasugrel versus ticagrelor in patients with acute myocardial infarction treated with primary percutaneous coronary intervention: clinical perspective;Motovska;Circulation,2016

4. “Real-world” comparison of prasugrel with ticagrelor in patients with acute coronary syndrome treated with percutaneous coronary intervention in the United States;Larmore;Catheter Cardiovasc Interv,2016

5. Real-world use of novel P2Y12 inhibitors in patients with acute myocardial infarction: a treatment paradox;Beigel;Cardiology,2016

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome: A Systematic Review and Meta-Analysis;The American Journal of Cardiology;2023-11

2. Rates of 30-Day and 90-Day Readmission Between Genotype-Optimal and Genotype-Suboptimal Antiplatelet Therapy Prescribing After Percutaneous Coronary Intervention;The American Journal of Cardiology;2023-09

3. Real-World Use and Outcomes of Oral Antiplatelets Among Patients with Acute Coronary Syndrome: A Retrospective Cohort Study;Drugs - Real World Outcomes;2021-11-15

4. Hospital and Operator Variation in Cardiac Rehabilitation Referral and Participation After Percutaneous Coronary Intervention: Insights From Blue Cross Blue Shield of Michigan Cardiovascular Consortium;Circulation: Cardiovascular Quality and Outcomes;2021-11

5. Comparative effectiveness and safety of prasugrel versus ticagrelor following percutaneous coronary intervention: An observational study;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2021-05-27